12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF and HIF-1α in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling pathway

Oncology Reports

Volumn 34, Issue 4, 2015, Pages 1755-1760

  Yang, Ying ^a   Cong, Huan ^a   Han, Cuicui ^a   Yue, Liling ^a   Dong, Haiying ^a   Liu, Jicheng ^a  

^a QIQIHAR MEDICAL UNIVERSITY   (China)

Author keywords

12 deoxyphorbol 13 palmitate; Hypoxia inducible factor 1 ; MCF 7 cells; PI3K Akt mTOR; Vascular endothelial growth factor

Indexed keywords

12 DEOXYPHORBOL 13 PALMITATE; ANTINEOPLASTIC AGENT; HAMARTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUBERIN; UNCLASSIFIED DRUG; VASCULOTROPIN; 12-DEOXYPHORBOL 13-PALMITATE; ANDROSTANE DERIVATIVE; HIF1A PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHORBOL ESTER; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; WORTMANNIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA INDUCIBLE FACTOR 1ALPHA GENE; MCF 7 CELL LINE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULOTROPIN GENE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANDROSTADIENES; ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MCF-7 CELLS; NEOVASCULARIZATION, PATHOLOGIC; PHORBOL ESTERS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939207869     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4166     Document Type: Article

References (42)

1. Yersal O and Barutca S: Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol 5: 412-424, 2014.
2. Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L and Tomao S: Triple-negative breast cancer: New perspectives for targeted therapies. Onco Targets Ther 8: 177-193, 2015.
3. Kubota Y: Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 61: 47-56, 2012.
4. X u HY, Pan YM, Chen ZW, Lin Y, Wang LH, Chen YH, Jie TT, Lu YY and Liu JC: 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway. J Ethnopharmacol 146: 724-733, 2013.
5. Goel HL and Mercurio AM: VEGF targets the tumour cell. Nat Rev Cancer 13: 871-882, 2013.
6. Kimbro KS and Simons JW: Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13: 739-749, 2006.
7. Zbytek B, Peacock DL, Seagroves TN and Slominski A: Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinology 5: 239-251, 2013.
8. Li M and Kim WY: Two sides to every story: The HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med 15: 187-195, 2011.
9. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J and Sawyers CL: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006.
10. Liu L, Ning X, Han S, Zhang H, Sun L, Shi Y, Sun S, Guo C, Yin F, Qiao T, et al: Hypoxia induced HIF-1 accumulation and VEGF expression in gastric epithelial mucosa cell: Involvement of ERK1/2 and PI3K/Akt. Mol Biol 42: 459-469, 2008 (In Russian).
11. Paplomata E and O'Regan R: The PI3K/AKT/mTOR pathway in breast cancer: Targets, trials and biomarkers. Ther Adv Med Oncol 6: 154-166, 2014.
12. Gomez-Pinillos A and Ferrari AC: mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am 26: 483-505, vii, 2012.
13. Moavero R, Coniglio A, Garaci F and Curatolo P: Is mTOR inhibition a systemic treatment for tuberous sclerosis? Ital J Pediatr 39: 57, 2013.
14. Huang J and Manning BD: The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. Biochem J 412: 179-190, 2008.
15. Fuckar D, Dekani A, Stifter S, Musta E, Krstulja M, Dobrila F and Jonji N: VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol 14: 49-55, 2006.
16. Ahluwalia A and Tarnawski AS: Critical role of hypoxia sensor-HIF-1 in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem 19: 90-97, 2012.
17. Mac Gabhann F, Qutub AA, Annex BH and Popel AS: Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdiscip Rev Syst Biol Med 2: 694-707, 2010.
18. Karar J and Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4: 51, 2011.
19. Serfontein J, Nisbet RE, Howe CJ and de Vries PJ: Evolution of the TSC1/TSC2-TOR signaling pathway. Sci Signal 3: ra49, 2010.
20. Weinstein IB and Joe AK: Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457, 2006.
21. Fakhrejahani E and Toi M: Antiangiogenesis therapy for breast cancer: An update and perspectives from clinical trials. Jpn J Clin Oncol 44: 197-207, 2014.
22. Kerbel RS: Tumor angiogenesis: Past, present and the near future. Carcinogenesis 21: 505-515, 2000.
23. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J and Tolentino MJ: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9: 210-216, 2003.
24. Fox SB, Generali DG and Harris AL: Breast tumour angiogenesis. Breast Cancer Res 9: 216, 2007.
25. Ventrice P, Leporini C, Aloe JF, Greco E, Leuzzi G, Marrazzo G, Scorcia GB, Bruzzichesi D, Nicola V and Scorcia V: Antivascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother 4 (Suppl 1): S38-S42, 2013.
26. Bausero P, Ben-Mahdi M, Mazucatelli J, Bloy C and Perrot-Applanat M: Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol 279: H2033-H2042, 2000.
27. X iao H, Gu Z, Wang G and Zhao T: The possible mechanisms underlying the impairment of HIF-1 pathway signaling in hyperglycemia and the beneficial effects of certain therapies. Int J Med Sci 10: 1412-1421, 2013.
28. Chen MH, Ren QX, Yang WF, Chen XL, Lu C and Sun J: Influences of HIF-l on Bax/Bcl-2 and VEGF expressions in rats with spinal cord injury. Int J Clin Exp Pathol 6: 2312-2322, 2013.
29. Yuan Y, Hilliard G, Ferguson T and Millhorn DE: Cobalt inhibits the interaction between hypoxia-inducible factor- and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-. J Biol Chem 278: 15911-15916, 2003.
30. Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW and Kim YJ: Melatonin suppresses tumor angiogenesis by inhibiting HIF-1 stabilization under hypoxia. J Pineal Res 48: 178-184, 2010.
31. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N and Johnson RS: Loss of HIF-1 in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6: 485-495, 2004.
32. Ahn GO, Seita J, Hong BJ, Kim YE, Bok S, Lee CJ, Kim KS, Lee JC, Leeper NJ, Cooke JP, et al: Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8. Proc Natl Acad Sci USA 111: 2698-2703, 2014.
33. Leung KW, Ng HM, Tang MK, Wong CC, Wong RN and Wong AS: Ginsenoside-Rg1 mediates a hypoxia-independent upregulation of hypoxia-inducible factor-1 to promote angiogenesis. Angiogenesis 14: 515-522, 2011.
34. Lu N, Hui H, Yang H, Zhao K, Chen Y, You QD and Guo QL: Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1 pathway. Eur J Pharm Sci 49: 220-226, 2013.
35. Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001.
36. X iao N, Qi XY, Tang LN, Tan LL, Chen YQ and Zhao HM: VEGF promotes cardiac stem cells differentiation into vascular endothelial cells via the PI3K/Akt signaling pathway. Artif Cells Nanomed Biotechnol 42: 400-405, 2014.
37. Agani F and Jiang BH: Oxygen-independent regulation of HIF-1: Novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets 13: 245-251, 2013.
38. Lee SH, Jee JG, Bae JS, Liu KH and Lee YM: A group of novel HIF-1 inhibitors, glyceollins, blocks HIF-1 synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding. J Cell Physiol 230: 853-862, 2015.
39. Fang J, Ding M, Yang L, Liu LZ and Jiang BH: PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 19: 2487-2497, 2007.
40. Huang J, Dibble CC, Matsuzaki M and Manning BD: The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 28: 4104-4115, 2008.
41. Massacesi C, di Tomaso E, Fretault N and Hirawat S: Challenges in the clinical development of PI3K inhibitors. Ann NY Acad Sci 1280: 19-23, 2013.
42. May FE: Novel drugs that target the estrogen-related receptor: Their therapeutic potential in breast cancer. Cancer Manag Res 6: 225-252, 2014.